ClinicalTrials.gov
ClinicalTrials.gov Menu

Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00869336
Recruitment Status : Completed
First Posted : March 26, 2009
Last Update Posted : June 21, 2011
Sponsor:
Information provided by:
Tinea Pharmaceuticals

Brief Summary:
To examine the safety and optimal duration of Luliconazole Cream 1% treatments for 14 days or 28 days to achieve "complete clearance" at 2 weeks post treatment.

Condition or disease Intervention/treatment Phase
Tinea Pedis Drug: Luliconazole Cream 1% - 2 wks Drug: Placebo Comparator -2 wks Drug: Luliconazole Cream 1% - 4 wks Drug: Placebo Comparator - 4 wks Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 147 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 2 Study - A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Duration Finding Study Evaluating the Efficacy and Safety of Two Week and Four Week Once Daily Treatment of Luliconazole Cream 1% in Patients With Tinea Pedis
Study Start Date : March 2009
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Luliconazole Cream 1% - 2 wks
Daily treatment with Luliconazole Cream 1% for 2 weeks
Drug: Luliconazole Cream 1% - 2 wks
Topical cream applied daily for 2 weeks
Experimental: Luliconazole Cream 1% - 4 wks
Daily treatment with Luliconazole Cream 1% for 4 weeks
Drug: Luliconazole Cream 1% - 4 wks
Topical cream applied daily for 4 weeks
Placebo Comparator: Placebo Comparator - 2 wks
Daily treatment with Vehicle Cream for 2 weeks
Drug: Placebo Comparator -2 wks
Placebo cream applied daily for 2 weeks
Placebo Comparator: Placebo Comparator - 4 wks
Daily treatment with Vehicle Cream for 4 weeks
Drug: Placebo Comparator - 4 wks
Placebo cream applied daily for 4 weeks



Primary Outcome Measures :
  1. Proportion of subjects who achieve complete clearance at 2 weeks post treatment [ Time Frame: Two weeks post treatment ]

Secondary Outcome Measures :
  1. Proportion of subjects who achieve effective treatment at 2 and 4 weeks post treatment [ Time Frame: 2 and 4 weeks post treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects of either gender must be 12 years of age or older.
  2. Subjects with a clinical diagnosis of interdigital tinea pedis on one or both feet characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling, and mild pruritus) based on signs and symptoms.
  3. Subjects with a mycological diagnosis of interdigital tinea pedis confirmed by the detection of fungal hyphae on a microscopic KOH wet mount
  4. Females of child-bearing potential must have a negative urine pregnancy test and must agree to use an effective form of contraception

Exclusion Criteria:

  1. Subjects with moccasin (dry type) tinea pedis; with concomitant onychomycosis of the fingernails and/or toenails on the evaluated foot, with severe dermatophytoses, a concurrent tinea infection or bacterial skin infection on the evaluated foot;
  2. Female subjects who are pregnant and/or nursing or planning a pregnancy during the course of the trial.
  3. Subjects who are immunocompromised (due to disease, e.g., HIV or medications
  4. Subjects with a history of intolerance or hypersensitivity to imidazole compounds or the inactive components of the cream;
  5. Subjects with a life-threatening condition (e.g., autoimmune deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months.
  6. Subjects using the following medications:

    1. topical antifungal agent within 30 days of the baseline visit
    2. systemic antifungals within 8 weeks of the baseline visit (8 months for oral terbinafine)
    3. topical corticosteroid in treatment area(s) within 30 days of the baseline visit.
    4. systemic corticosteroids within 30 days of the baseline visit;
    5. any other topical medicated topical treatments to the treatment area(s) within 7 days of baseline visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00869336


Locations
United States, Minnesota
Fridley, Minnesota, United States, 55432
United States, Oregon
Portland, Oregon, United States, 97210
United States, Texas
Austin, Texas, United States, 78759
College Station, Texas, United States, 77840
Sponsors and Collaborators
Tinea Pharmaceuticals

Responsible Party: Tinea Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00869336     History of Changes
Other Study ID Numbers: TP-0801
First Posted: March 26, 2009    Key Record Dates
Last Update Posted: June 21, 2011
Last Verified: June 2011

Keywords provided by Tinea Pharmaceuticals:
Tinea Pedis
Athlete's Foot

Additional relevant MeSH terms:
Tinea
Tinea Pedis
Dermatomycoses
Skin Diseases, Infectious
Infection
Mycoses
Skin Diseases
Foot Dermatoses
Foot Diseases
Pruritus
Skin Manifestations
Signs and Symptoms